
Peer reviewed version

Link to published version (if available):
10.1001/jamacardio.2017.5205

Link to publication record in Explore Bristol Research
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via AMA at https://jamanetwork.com/journals/jamacardiology/fullarticle/2670752 . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
Omega-3 fatty acids and risk of cardiovascular disease: meta-analysis of 10 trials involving 77,900 individuals

Theingi Aung FRCP¹,², Jim Halsey BSc¹, Daan Kromhout PhD³, Hertzel C Gerstein MD⁴, Roberto Marchioli MD⁵,⁶, Luigi Tavazzi MD⁷, Johanna M Geleijnse PhD³, Bernhard Rauch MD⁸, Andrew Ness FFPHM⁹, Pilar Galan MD¹⁰, Emily Y Chew MD¹¹, Jackie Bosch PhD⁴, Rory Collins FRCP¹, Sarah Lewington DPhil¹, Jane Armitage FRCP¹, Robert Clarke FRCP¹ for the Omega-3 Treatment Trialists’ Collaboration.

¹ Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), and MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; ² Department of Endocrinology, Royal Berkshire Hospital, Reading, UK; ³ Department of Human Nutrition, Wageningen University, Wageningen, Netherlands; ⁴ Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; ⁵ Cardiovascular Renal Metabolic (CVRM) Therapeutic Area, Medical Strategy and Science, Therapeutic Science and Strategy Unit (TSSU), Quintiles, Milan, Italy; ⁶ Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; ⁷ Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy; ⁸ Institut für Herzinfarktforschung Ludwigshafen (IHF), Ludwigshafen, Germany; ⁹ National Institute for Health Research Biomedical Research Unit in Nutrition, Diet and Lifestyle at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK; ¹⁰ Sorbonne Paris Cité Epidemiology and Biostatistics Research Center (CRESS), Nutritional Epidemiology Research Team (EREN), Inserm U1153, Inra U1125, Cnam, Paris 13 University, Bobigny, France; ¹¹ National Eye Institute, National Institutes of Health, Building 10, CRC Room 3-2531, 10 Center Drive, MSC 1204, Bethesda, MD 20892-1204, USA.

Please confirm that the details for you and your affiliation are correct and return the form to me (robert.clarke@ndph.ox.ac.uk).

☐ Yes  ☐ No

If no, please correct or amend this page using track changes before returning it to robert.clarke@ndph.ox.ac.uk.

Name: ...........................................
The following are Members of the OMEGA-3 Treatment Trialists’ Collaboration

**Secretariat:** Theingi Aung FRCP, Jim Halsey BSc, Rory Collins FRCP, Sarah Lewington DPhil, Jane Armitage FRCP, Robert Clarke FRCP. Nuffield Department of Population Health, University of Oxford, Oxford, UK

**Age-Related Eye Disease Study 2 (AREDS-2):** Denise E Bonds MD MPH, Molly Harrington MS, Emily Y Chew MD. National Eye Institute, National Institutes of Health, Bethesda, MD, USA

**Supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids trial (SU.FOL.OM3):** Pilar Galan MD, Serge Hercberg MD. Sorbonne Paris Cité Epidemiology and Biostatistics Research Center (CRESS), Inserm U1153, Paris, France

**ALPHA OMEGA:** Daan Kromhout PhD, Eric J Giltray MD; Johanna M Geleijnse PhD. Wageningen University, Wageningen, Netherlands

**OMEGA:** Bernard Rauch MD. Institut für Herzinfarktforschung Ludwigshafen (IHF), Ludwigshafen, Germany

**Risk and Prevention Study (R&P):** Roberto Marchioli MD; Gianni Tognoni MD; Maria Carla Roncaglioni MD. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

**GISSI Heart Failure Trial (GISSI-HF):** Luigi Tavazzi MD, Aldo P Maggioni MD; Roberto Marchioli MD; Dr Donata Lucci BS. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

**Outcome Reduction With Initial Glargine Intervention (ORIGIN):** Jackie Bosch MSc; Hertzel Gerstein MD. McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada

**GISSI-Prevenzione (GISSI-P):** Roberto Marchioli MD; Aldo P Maggioni MD; Gianni Tognoni MD. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

**Diet and Reinfarction Trial (DART):** Andrew Ness MRCP. University of Bristol, Bristol, UK

---

Please verify that the full names, degrees and affiliations for collaborators in your trial listed above are correct and return the form to me.

☐ Yes  ☐ No

If no, please correct or amend this page using track changes before returning it to robert.clarke@ndph.ox.ac.uk.